Once-daily beta2-agonists or ultra long-acting beta2-agonists (LABAs) are under development for asthma and COPD. Arcapta Neohaler (indacaterol) is the only once-daily ultra-LABA approved for COPD maintenance (http://goo.gl/3RJyu).Ultra-LABAs
Ultra-LABAs under development for treatment of asthma and COPD include:

LABA plus LAMA combinationsSeveral options for once-daily dual-action ultra LABA plus LAMA combination products are currently being evaluated. Dimer molecule in which both LABA and LAMA are present is called M3 antagonist-beta2 agonist (MABA) bronchodilators http://bit.ly/8behHIndacaterol advantages
Single doses of indacaterol is effective for 24-h bronchodilation and well tolerated in patients with persistent asthma http://bit.ly/1ahQOx. The Risks and Benefits of Indacaterol - NEJM review and 16-min podcast. NEJM, 2011.

Indacaterol had a greater effect than formoterol on FEV1: 17.7% vs. 7.5%, respectively, from pre-dose. Comparison of once daily indacaterol and twice daily formoterol: a greater effect of indacaterol on resting IC and FEV1 http://bit.ly/3kqFL1

Indacaterol showed bronchodilator efficacy throughout the full 24-hour period, rapid onset of action, good safety http://bit.ly/lbW9E

Mast cell stabilization may constitute another therapeutic benefit of indacaterol in addition to bronchodilation http://bit.ly/1mcHFo

Bronchodilator efficacy of indacaterol at 24 h post-dose was at least as efficacious as formoterol 12 microg BID http://bit.ly/lTmpr

Indacaterol trough FEV1 levels compared favorably with the improvement seen with tiotropium in COPD patients http://bit.ly/3DRXK

Indacaterol as a partnering agent for combinations: LABA/ICS and LABA/LAMAIndacaterol is an attractive partnering agent for fixed combinations in both asthma and COPD, e.g. daily ICS or LAMA http://bit.ly/L70cr

Subscribe and Connect

About Us

Disclaimer: All opinions expressed here are those of their authors and not of their employer. The information provided here is for educational purposes only and is not intended to provide medical advice. By accessing the web site, the visitors acknowledge that there is no physician-patient relationship between them and the authors.